FAQ: Quantum BioPharma Ltd. (NASDAQ: QNTM) Legal Victory and Company Overview

What was the outcome of the legal dispute between Quantum BioPharma Ltd. and its former CEO?

The Court of Appeal for Ontario fully dismissed a reconsideration motion filed by former CEO Dr. Raza Bokhari, who was terminated for cause in 2021. This follows a previous arbitration loss by Bokhari, resulting in a total cost award of approximately C$2.81 million plus interest, now exceeding C$3 million with additional court-awarded costs.

How is Quantum BioPharma Ltd. enforcing the judgment in the U.S.?

Quantum BioPharma has initiated U.S. collection proceedings, leading to a judgment in its favor by the U.S. District Court for the Eastern District of Pennsylvania. Bokhari’s appeal is ongoing with a stay in place, secured by a supersedeas bond of more than $2.8 million.

What is Quantum BioPharma Ltd. focused on?

Quantum BioPharma is dedicated to developing innovative treatments for neurodegenerative, metabolic, and alcohol misuse disorders, with drug candidates in various development stages. Its subsidiary, Lucid Psycheceuticals Inc., is researching Lucid-MS, a compound targeting myelin degradation in multiple sclerosis.

What is UNBUZZD and how is Quantum BioPharma Ltd. involved?

UNBUZZD is a product invented by Quantum BioPharma, which spun out its OTC version to Celly Nutrition Corp. Quantum BioPharma retains a 25.71% ownership in Celly Nutrition as of June 30, 2024, and receives royalty payments from UNBUZZD sales, with terms adjusting after $250 million in payments.

Where can investors find the latest news about Quantum BioPharma Ltd.?

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.

What are the implications of the legal victory for Quantum BioPharma Ltd.?

The dismissal of the reconsideration motion and the enforcement of the judgment in the U.S. strengthen Quantum BioPharma’s legal and financial position. It also allows the company to focus more resources on its core mission of developing innovative biopharmaceutical solutions.

Who is involved in the legal dispute with Quantum BioPharma Ltd.?

The dispute involves Quantum BioPharma Ltd. and its former CEO, Dr. Raza Bokhari, who was terminated for cause in 2021. The legal proceedings have taken place in the Court of Appeal for Ontario and the U.S. District Court for the Eastern District of Pennsylvania.

What is Lucid-MS and its significance?

Lucid-MS is a patented new chemical entity developed by Quantum BioPharma’s subsidiary, Lucid Psycheceuticals Inc., shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, making Lucid-MS a potential breakthrough treatment.